Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has been awarded an A$1.4 million tax refund under the Australian Government's Research and Development (R&D) Tax Incentive Scheme.

The refund covers eligible R&D activities for the year ending December 31, 2023.

Incentivising research

The R&D Tax Incentive Scheme encourages Australian companies to engage in research by offering a refundable tax offset on their initiatives, helping businesses recover some of their R&D-related expenses.

Anteris plans to use the refund to continue the development of its key technologies, including the ADAPT® tissue, DurAVR® transcatheter heart valve (THV) and the ComASUR® Delivery System.

Read: Anteris Technologies' transcatheter heart valve continues to demonstrate its potential

These technologies are essential to the company's upcoming FDA pivotal trial for the DurAVR® THV, aimed at treating severe aortic stenosis.

Leader in structural heart market

Anteris is a leader in the structural heart market, focused on providing innovative solutions to treat heart disease.

Its DurAVR® THV, developed in collaboration with top cardiologists and cardiac surgeons, is the first transcatheter aortic valve to use a single piece of bioengineered tissue, closely mimicking the function of a healthy human valve.

With the continuing support of the R&D tax refund, Anteris is advancing towards delivering superior clinical outcomes for patients with unmet needs in the structural heart market.

Watch: Anteris Technologies and v2vmedtech achieve concept lock for new TEER system